<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392388</url>
  </required_header>
  <id_info>
    <org_study_id>C20-26</org_study_id>
    <secondary_id>2020-A01195-34</secondary_id>
    <nct_id>NCT04392388</nct_id>
  </id_info>
  <brief_title>Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis</brief_title>
  <acronym>SAPRIS-SERO</acronym>
  <official_title>Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in
      the French population using serological tests and to assess the determinants of infection
      from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to assess the cumulative incidence of infection in the general
      population using dried blood spot sampling.

      The secondary objectives are:

        -  To identify factors associated with a positive SARS-CoV-2 infection (positive serology)
           and to characterize the durability of the serological response to SARS-CoV-2

        -  To identify associations of symptoms predictive of a SARS-CoV-2 infection

        -  To estimate the health care use assoicated with a SARS-CoV-2 infection

        -  To estimate the fraction of sub-clinical infections or infections not captured by the
           healthcare system;

        -  To study the acceptability of a mass anti-SARS-CoV-2 serological testing and the impact
           of its result, linked with social inequalities in health;

        -  To estimate the individual and collective impact of containment and other preventive
           measures on the risk of SARS-CoV-2 infection;

        -  To study the impact of social and territorial inequalities on seroprevalence levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of SARS-Cov2 infection in the general population.</measure>
    <time_frame>8 months</time_frame>
    <description>To assess the cumulative incidence of SARS-Cov2 infection in the general population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the &quot;immune&quot; fraction of the population and the durability of immunity</measure>
    <time_frame>8 months</time_frame>
    <description>Besides to Characterize the &quot;immune&quot; fraction of the population and the durability of immunity, the other secondary outcomes are:
Identify associations of predictive symptoms of SARS-Cov2 infection Estimate the use of care rate in connection with a SARS-Cov2 infection Estimate the fraction of sub-clinical infections or infections not captured by the healthcare system; Study the acceptability of a mass anti-SARS-Cov2 serological test and the impact of its result, link with social inequalities in health; Estimate the individual and collective impact of containment and other barrier measures on the risk of seroconversion; Study the impact of social and territorial inequalities on the level of seroprevalence.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">110000</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>SAPRIS-SERO</arm_group_label>
    <description>SAPRIS-SERO enrolls participants from cohorts entitled: Constances, E3N-E4N, ELFE, Epipage 2 and NutriNet-Santé.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non applicable</intervention_name>
    <description>to collect data from questionnaires and to collect serological samples</description>
    <arm_group_label>SAPRIS-SERO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serology samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from cohorts entitled : Constances, E3N-E4N, ELFE, Epipage 2 and
        NutriNet-Santé
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non applicable, already enrolled in the cohorts

        Exclusion Criteria:

          -  non applicable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Carrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inserm - Sorbonne Université</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Carrat</last_name>
    <phone>+33 (0)1 44 73 84 44</phone>
    <email>fabrice.carrat@inserm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inserm</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Carrat</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV2</keyword>
  <keyword>cohort</keyword>
  <keyword>containment</keyword>
  <keyword>serology</keyword>
  <keyword>prevention</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD sharing is managed via the cohorts (Constances, E3N/E4N, NutriNetSante, Elfe/Epipage2) specific governing bodies.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

